Published in Vaccine Weekly, October 2nd, 2002
Michael J. Caulfield and colleagues working at Merck Research Laboratories in West Point, Pennsylvania, evaluated several formulations of an HIV gag-based vaccine.
They found that several of the vaccine candidates tested elicited long-term antigen-specific cytotoxic T-cell activity, according to their report in the October 2002 edition of the Journal of Virology.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.